We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock

Delisted

VYNT was delisted on the 12th of May, 2023.

32 hedge funds and large institutions have $10.5M invested in Vyant Bio, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

11% less funds holding

Funds holding: 3632 (-4)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

36% less capital invested

Capital invested by funds: $16.3M → $10.5M (-$5.81M)

43% less call options, than puts

Call options by funds: $8K | Put options by funds: $14K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
32
Holders Change
-4
Holders Change %
-11.11%
% of All Funds
0.89%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
4
Increased
14
Reduced
6
Closed
6
Calls
$8K
Puts
$14K
Net Calls
-$6K
Net Calls Change
+$22K

VYNT Hedge Fund Activity: Q3 2015 in Review

32 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2015, worth a combined $10.5M — down 36% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of VYNT and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 14 added.

The largest buyer was Granite Investment Partners, adding an estimated $491K. The largest seller was Royce & Associates, cutting an estimated $403K.

  • 32 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2015, down from 36 in Q2 2015.
  • Funds reported $10.5M of Vyant Bio, Inc. Common Stock stock for Q3 2015, down 36% quarter-over-quarter.
  • 4 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2015 and 6 closed out, a net change of -2 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q3 2015 was Granite Investment Partners, an estimated $491K added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q3 2015 was Royce & Associates, an estimated $403K sold.

Based on aggregated 13F filings for Q3 2015.